KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Eli Lilly (LLY) Sales of Property, Plant and Equipment (2015 - 2016)

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Sales of Property, Plant and Equipment (Qtr)
1	Novartis Ag	107,124,802.25 Bn	107,124,802.25 Bn	-	5.00 Mn
2	Eli Lilly	969.00 Bn	963.72 Bn	16.22 Bn	-
3	Johnson & Johnson	539.46 Bn	517.41 Bn	15.96 Bn	29.00 Mn
4	AbbVie	376.92 Bn	367.57 Bn	10.78 Bn	-
5	Merck	285.00 Bn	279.35 Bn	12.09 Bn	-
6	Amgen	177.58 Bn	165.55 Bn	5.87 Bn	-
7	Gilead Sciences	163.22 Bn	155.50 Bn	5.52 Bn	-
8	Pfizer	145.86 Bn	133.09 Bn	-1.21 Bn	-
9	Bristol Myers Squibb	111.90 Bn	101.44 Bn	8.07 Bn	-
10	Gsk	88.34 Bn	83.66 Bn	-	-

Historic Data

Download Data 🔒

Date	Value
Dec 31, 2016	73.40 Mn
Dec 31, 2016	73.40 Mn
Mar 31, 2015	410.00 Mn
Mar 31, 2015	410.00 Mn